The Unconventional UK Market—Don’t Miss the Starting Line

The biggest hurdle in the UK market is not regulation, but the procurement system.

Many Chinese companies have long relied on a straightforward approach: identify a strong distributor, and let the distributor handle sales to hospitals. This model has proven effective across Southeast Asia, the Middle East, and Latin America.

But it’s not feasible in the UK!

The United Kingdom has more than 1,000 hospitals, but the purchasing entity is not the hospitals themselves; it is… NHS Trust 。

What is a Trust? It is not a single hospital, but rather a hospital group. Across England, approximately 200 Trusts manage more than 1,000 hospitals and community facilities, implementing unified procurement, centralized budgeting, and coordinated decision-making.

This means you don’t need to persuade the directors of 1,000 hospitals—only the procurement systems of 200 trusts.

Many Chinese companies have attended numerous UK trade shows but still haven’t found distributors; the root of the problem isn’t the products—it’s that they haven’t targeted the right contacts.

The decision-making process for medical procurement in the United Kingdom is extremely lengthy. From the articulation of clinical needs to the final contract signing, it typically takes about one year.

The process generally follows this sequence: clinical staff submit a request → the Clinical Engineering Department reviews technical specifications → the Procurement Department evaluates suppliers → NHS budget approval → final procurement.

The key point is: physicians can only “recommend” but cannot “authorize” purchases. The decision to buy or not rests with the clinical engineers and the procurement team.

The Clinical Engineering Manager establishes equipment admission criteria and technical requirements. The Head of Medical Device Safety and Compliance evaluates new devices and recommends their procurement. Meanwhile, the Procurement Manager focuses on pricing and contract terms. These three roles are the true decision-makers in medical device acquisition.

In the Southeast Asian and Middle Eastern markets, which Chinese companies know well, securing distributors essentially resolves the sales challenge. But in the UK, distributors don’t sell products.

British distributors offer: NHS relationships, clinical resources, tendering expertise, training programs, and after-sales support. Essentially, they function as sales and service platforms—responsible for securing hospital presentations, managing tenders, and providing post‑sale assistance.

However, purchasing decisions are not made by the distributors. It is Trust that determines what to buy, and the distributors are responsible for delivering it. It’s not that you approach a distributor and they help you sell into hospitals—rather, you must first be integrated into Trust’s procurement system before the distributor can execute on your behalf.

If you reverse this order, everything will be wrong.

In June 2026, the NHS launched a new “Value-Based Procurement Framework.”

In the past, NHS procurement was primarily driven by price. Today, the evaluation criteria have expanded to include patient clinical outcomes, patient experience, environmental impact, and life-cycle costs.

Relying solely on “low prices” is no longer sufficient. The key questions are: can we reduce readmission rates, shorten hospital stays, and ensure long-term supply-chain reliability...?

“Value” is not the same as “value for money.” It equals “better outcomes + a more reasonable price + more sustainable services.” This is currently at the heart of the NHS’s priorities.

Once we’ve understood the procurement logic, we’ve identified the procurement decision‑making chain within the NHS Trusts, There are three key stakeholder groups: clinical engineers, procurement managers, and NHS supply chain personnel. And the audience of EBME Expo happens to comprise precisely these three groups. Detailed insights are provided below.

EBME EXPO 2027 | Gain direct access to the UK’s core medical device procurement network—booth reservations now open!

Jiayu International has been appointed.

↓ ↓ ↓

Official exclusive agent for the entire territory of China for EBME Expo 2027

We are your trusted partner for entering the UK market and showcasing at EBME.

In a nutshell: Exhibiting at EBME essentially means engaging directly with Trust’s procurement system—targeting decision-makers rather than distributors.

The NHS is the world’s largest single-payer healthcare system. It operates on an annual budget of £215 billion, with £64 billion allocated to infrastructure investment, an expansion of 170 community diagnostic centres, and a total of 29 million diagnostic procedures per year.

—The key lies in—

These are not “hot trends.”

Rather, it is a structural demand that has persisted for decades.

Compared with other European markets, the UK exhibits a higher degree of centralized procurement than Germany, is more open than France, and—while its profit margins are lower than Saudi Arabia’s—offers a more stable market. Once you establish a foothold in a trust, orders are steady and pricing remains favorable.

As the NHS shifts its procurement toward “maximum value,” Chinese companies have a unique opportunity: to redefine the place of “Made in China” in the NHS’s eyes through superior products, more comprehensive services, and more sustainable supply chains.

So the UK market

It’s not about who arrives first.

It’s about who lasts the longest.